Alternative splicing as a biomarker and potential target for drug discovery.

Acta Pharmacol Sin

School of Pharmaceutical Sciences, Xiamen University at Xiang'an, Xiamen 361102, China.

Published: October 2015

Alternative splicing is a key process of multi-exonic gene expression during pre-mRNA maturation. In this process, particular exons of a gene will be included within or excluded from the final matured mRNA, and the resulting transcripts generate diverse protein isoforms. Recent evidence demonstrates that approximately 95% of human genes with multiple exons undergo alternative splicing during pre-mRNA maturation. Thus, alternative splicing plays a critical role in physiological processes and cell development programs, and.dysregulation of alternative splicing is highly associated with human diseases, such as cancer, diabetes and neurodegenerative diseases. In this review, we discuss the regulation of alternative splicing, examine the relationship between alternative splicing and human diseases, and describe several approaches that modify alternative splicing, which could aid in human disease diagnosis and therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648177PMC
http://dx.doi.org/10.1038/aps.2015.43DOI Listing

Publication Analysis

Top Keywords

alternative splicing
32
alternative
8
pre-mrna maturation
8
human diseases
8
splicing
7
splicing biomarker
4
biomarker potential
4
potential target
4
target drug
4
drug discovery
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!